Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 208

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 208
---
 Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia. Initial Public Offering On July 14, 2023, the Company closed its initial public offering consisting of 23,585units at a price of $ 318.00per unit for $ 6,454,325in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $ 365.70per share (a “Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $ 381.60per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants were immediately exercisable on the date of issuance and will expire five yearsfrom the date of issuance (July 12, 2023 to July 12, 2028). The Company granted the underwriters a 45-day over-allotment option to purchase up to 3,538shares of the Company’s common stock at a price of $ 316.80per share and/or 3,538Tradeable Warrants at a price of $ 0.60per Tradeable Warrant and/or 3,538Non-tradeable Warrants at $ 0.60per Non-tradeable Warrant, or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment and purchased an additional 1,678Tradeable Warrants and 1,678Non-tradeable Warrants. The Company also issued to the underwriters warrants to purchase 1,416shares of the Company’s common stock, at an exercise price of $ 349.80per share, equal to 110% of the offering price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five yearsfrom the date of issuance (July 14, 2023 to July 14, 2028). The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended